New Study Investigates the Impact of Prenatal SSRI Exposure on Brain Structure in Older Children
Maternal SSRI use during pregnancy may be associated with altered brain development in children; however, this study cannot fully rule out contributions of confounding genetic and enviromental factors.
Disparities in Maternal-Infant Drug Testing
More infants who were exposed to strong agonists and opioids with long half-lives, including methadone, developed neonatal opioid withdrawal syndrome.
Resources for Parents with Infants in the Neonatal Intensive Care Unit
List of resources for families with infants in the Neonatal Intensive Care Unit.
Zuranolone: A novel postpartum depression treatment, with lingering questions
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on zuranolone for postpartum depression with Ob.Gyn News on August 15, 2023.
A New Study Investigates the Impact of a Drospirenone-Only Contraceptive Pill On Postpartum Mood
Postpartum women taking a drospirenone-only contraceptive pill experienced a decrease in depressive symptoms.
Using Predictive Modeling to Examine IV Ketamine and Esketamine for the Prevention of Postpartum Depression
Intravenous ketamine or esketamine given at the time of cesarean delivery reduced risk for postpartum depression; predictive models are needed to determine which women are most likely to benefit from this intervention.
FDA Approves Zuranolone for the Treatment of Postpartum Depression
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
Weekly Roundup for August 4, 2023: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.